Soleus Capital Management, L.P. Aeglea Bio Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 13, 2020	SELL	$6.51 - $9.33 $2.41 Million - $3.45 Million	-369,852 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$4.01 - $11.04 $668,246 - $1.84 Million	-166,645 Reduced 31.06%	369,852 $3.42 Million
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $274,945 - $664,255	78,332 Added 17.1%	536,497 $2.5 Million
Q4 2019 Feb 14, 2020	BUY	$7.23 - $8.55 $3.31 Million - $3.92 Million	458,165 New	458,165 $3.5 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.